Dr. Alison Stopeck, MD
Claim this profileStony Brook University Cancer Center
Studies Breast Cancer
Studies Chemotherapy
5 reported clinical trials
8 drugs studied
Area of expertise
1Breast Cancer
Stage III
Stage II
HER2 negative
2Chemotherapy
Stage III
Affiliated Hospitals
Clinical Trials Alison Stopeck, MD is currently running
DNA-Guided Adjuvant Therapy
for Breast Cancer
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Recruiting1 award Phase 29 criteria
Contrast-Enhanced Mammography
for Breast Cancer
The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant chemotherapy on pathologic complete response rates. The device used to obtain CEDM+CEDBT images is called Siemens MAMMOMAT. This device produces two-dimensional (2D) images, as in a normal mammogram, but also collects additional images for digital breast tomosynthesis (DBT), which produces a three-dimensional (3D) image of the breast in the form of image slices. DBT allows the radiologist to "see through" the breast tissue for better detection and localization of breast cancer. By looking at both the CEDM images and the CEDBT images, a radiologist may be able to better detect residual breast cancer in a more cost-effective manner. Participation may last up to 18 weeks. Study procedures for this research are: * Undergoing 1-2 mammograms during and/or after your chemotherapy, but before primary breast surgery. * Before each mammogram, have a radiology technician inject a liquid contrast agent by inserting a needle into a vein. The chemotherapy port cannot be used to receive the contrast agent * Let the research team record information from your medical record related to your condition and the treatment you receive. * Give permission to collect leftover tissue from your diagnostic biopsy and breast surgery.
Recruiting1 award Phase < 1
More about Alison Stopeck, MD
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Alison Stopeck, MD has experience with
- Placebo
- Denosumab
- Sulindac Pill
- Palbociclib
- Fulvestrant
- Tucatinib
Breakdown of trials Alison Stopeck, MD has run
Breast Cancer
Chemotherapy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alison Stopeck, MD specialize in?
Alison Stopeck, MD focuses on Breast Cancer and Chemotherapy. In particular, much of their work with Breast Cancer has involved Stage III patients, or patients who are Stage II.
Is Alison Stopeck, MD currently recruiting for clinical trials?
Yes, Alison Stopeck, MD is currently recruiting for 2 clinical trials in Stony Brook New York. If you're interested in participating, you should apply.
Are there any treatments that Alison Stopeck, MD has studied deeply?
Yes, Alison Stopeck, MD has studied treatments such as Placebo, Denosumab, Sulindac Pill.
What is the best way to schedule an appointment with Alison Stopeck, MD?
Apply for one of the trials that Alison Stopeck, MD is conducting.
What is the office address of Alison Stopeck, MD?
The office of Alison Stopeck, MD is located at: Stony Brook University Cancer Center, Stony Brook, New York 11794 United States. This is the address for their practice at the Stony Brook University Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.